Redeye provides an initial take following Paxman’s Q2 2025 report. The quarterly figures were slightly below our projections, although we had anticipated forecasting challenges this quarter. Overall, we consider the report to be decent. We expect to make minor downward revisions to our short-term estimates but see no material impact on our valuation.
LÄS MER
